<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01136772</url>
  </required_header>
  <id_info>
    <org_study_id>#6017</org_study_id>
    <secondary_id>R01MH081107</secondary_id>
    <nct_id>NCT01136772</nct_id>
  </id_info>
  <brief_title>A Comparison of Long-acting Injectable Medications for Schizophrenia</brief_title>
  <acronym>ACLAIMS</acronym>
  <official_title>A Comparison of Long-Acting Injectable Medications for Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to compare the &quot;real-world&quot; effectiveness of two
      FDA-approved and widely used long-acting injectable antipsychotic medications (paliperidone
      palmitate and haloperidol decanoate) in patients with schizophrenia or schizoaffective
      disorder who are expected to benefit from the improved medication compliance associated with
      injectable medications. The goal is to evaluate the effects of the medications on outcomes of
      importance to patients (relapse, symptoms, adverse effects, functioning) as well as policy
      makers (all of the above plus costs).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this comparative effectiveness research study is to learn more about different
      medications called antipsychotics that are used to treat schizophrenia or schizoaffective
      disorder. Specifically, we are looking at long-acting medications that are given by injection
      every month, instead of being taken by mouth every day. In this multi-site study, we are
      comparing the risk and benefits of two FDA-approved long-acting injectable medications
      (paliperidone palmitate and haloperidol decanoate). Study participants with schizophrenia or
      schizoaffective disorder are expected to benefit from the improved medication schedule.

      This study aims to enroll 360 individuals with schizophrenia or schizoaffective disorder for
      whom treatment with a long-acting injectable antipsychotic medication is likely to be
      helpful. Study participants will be randomly assigned to treatment with either paliperidone
      palmitate and haloperidol decanoate for up to 24 months. Participants will have an equal
      chance of being assigned to each medication, however participants will not know which
      medication they are taking.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy Failure</measure>
    <time_frame>24 months</time_frame>
    <description>Efficacy failure as indicated by psychiatric hospitalization, need for crisis intervention, clinical decision that oral antipsychotic medication cannot be discontinued in less than eight weeks, a clinical decision to discontinue the medication due to inadequate benefit, or the ongoing or repeated need for adjunctive antipsychotic medication.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Psychiatric Symptoms</measure>
    <time_frame>Baseline to 6 months</time_frame>
    <description>The Positive and Negative Syndrome Scale measures the core symptoms associated with schizophrenia. The measure includes 30 items rated from 1=absent to 7=extremely severe. Full range of scores is 30-210 with higher scores representing more severe illness. Reductions in symptoms over time represent improvement.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">311</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizoaffective Disorder</condition>
  <arm_group>
    <arm_group_label>Paliperidone palmitate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intramuscular injections of paliperidone palmitate 39-234 mg every month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Haloperidol decanoate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intramuscular injections of haloperidol decanoate 25-200 mg every month</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>haloperidol decanoate</intervention_name>
    <description>haloperidol decanoate injections, 25-200 mg once a month</description>
    <arm_group_label>Haloperidol decanoate</arm_group_label>
    <other_name>Haldol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paliperidone palmitate</intervention_name>
    <description>Paliperidone palmitate injections, 39 mg - 234 mg once a month</description>
    <arm_group_label>Paliperidone palmitate</arm_group_label>
    <other_name>Invega Sustenna</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of schizophrenia or schizoaffective disorder as defined by DSM-IV-TR
             criteria

          -  Age 18-65 years

          -  Capacity to provide informed consent

          -  Patients who are likely to benefit from treatment with long-acting injectable
             paliperidone palmitate or haloperidol decanoate

          -  Women of child bearing potential must have a negative serum pregnancy test at the
             Screening Visit.

        Exclusion Criteria:

          -  Patients who are currently stable and doing well on an antipsychotic regimen

          -  Patients not expected to benefit from the study medications due to past experience
             with risperidone, paliperidone or haloperidol

          -  Patients with tardive dyskinesia that is moderate or severe

          -  Patients with any medical condition that, in the judgment of the investigator, might
             preclude safe completion of the study

          -  Women who are pregnant or breastfeeding

          -  Patients with mental retardation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Stroup, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joseph P McEvoy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Palo Alto Heathcare Systems</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University/Connecticut Mental Health Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Georgia</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa Hospital</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Insights, Inc.</name>
      <address>
        <city>Glen Burnie</city>
        <state>Maryland</state>
        <zip>21061</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John D. Dingell VA Medical Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sparrow St. Lawrence Hospital, Michigan State University Psychiatry</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48915</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kansas City Veterans Affairs Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Creighton University Dept. of Psychiatry</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Foundation for Mental Hygiene</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Umstead Hospital/Duke University</name>
      <address>
        <city>Butner</city>
        <state>North Carolina</state>
        <zip>27509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Behavioral Care</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louis Stokes Cleveland VA Medical Center</name>
      <address>
        <city>Brecksville</city>
        <state>Ohio</state>
        <zip>44141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philadelphia VA Medical Center-116A</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Texas Veterans Health Care System</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <zip>78711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frontier Institute</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Puget Sound Health Care System</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98493</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Puerto Rico</country>
  </removed_countries>
  <results_reference>
    <citation>McEvoy JP, Byerly M, Hamer RM, Dominik R, Swartz MS, Rosenheck RA, Ray N, Lamberti JS, Buckley PF, Wilkins TM, Stroup TS. Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial. JAMA. 2014 May 21;311(19):1978-87. doi: 10.1001/jama.2014.4310. Erratum in: JAMA. 2014 Oct 8;312(14):1473.</citation>
    <PMID>24846035</PMID>
  </results_reference>
  <results_reference>
    <citation>Rosenheck RA, Leslie DL, Sint KJ, Lin H, Li Y, McEvoy JP, Byerly MJ, Hamer RM, Swartz MS, Stroup TS. Cost-Effectiveness of Long-Acting Injectable Paliperidone Palmitate Versus Haloperidol Decanoate in Maintenance Treatment of Schizophrenia. Psychiatr Serv. 2016 Oct 1;67(10):1124-1130. Epub 2016 Jun 1.</citation>
    <PMID>27247177</PMID>
  </results_reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2010</study_first_submitted>
  <study_first_submitted_qc>June 2, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2010</study_first_posted>
  <results_first_submitted>March 25, 2015</results_first_submitted>
  <results_first_submitted_qc>April 7, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 24, 2015</results_first_posted>
  <last_update_submitted>September 6, 2016</last_update_submitted>
  <last_update_submitted_qc>September 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paliperidone Palmitate</mesh_term>
    <mesh_term>Haloperidol</mesh_term>
    <mesh_term>Haloperidol decanoate</mesh_term>
    <mesh_term>Decanoic acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Paliperidone Palmitate</title>
          <description>Intramuscular injections of paliperidone palmitate 39-234 mg every month</description>
        </group>
        <group group_id="P2">
          <title>Haloperidol Decanoate</title>
          <description>Intramuscular injections of haloperidol decanoate 25-200 mg every month</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="157"/>
                <participants group_id="P2" count="154"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="147">Includes all randomized participants who received at least one dose of the injectable medication</participants>
                <participants group_id="P2" count="147">Includes all randomized participants who received at least one dose of the injectable medication</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="116"/>
                <participants group_id="P2" count="110"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not receive injection</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not follow up after first injection</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline characteristics of modified intent-to-treat population (those who received at least one injection and attended one follow-up appointment)</population>
      <group_list>
        <group group_id="B1">
          <title>Paliperidone Palmitate</title>
          <description>Intramuscular injections of paliperidone palmitate 39-234 mg every month</description>
        </group>
        <group group_id="B2">
          <title>Haloperidol Decanoate</title>
          <description>Intramuscular injections of haloperidol decanoate 25-200 mg every month</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="145"/>
            <count group_id="B2" value="145"/>
            <count group_id="B3" value="290"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43" spread="12.6"/>
                    <measurement group_id="B2" value="45" spread="12.3"/>
                    <measurement group_id="B3" value="44" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                    <measurement group_id="B2" value="110"/>
                    <measurement group_id="B3" value="216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Efficacy Failure</title>
        <description>Efficacy failure as indicated by psychiatric hospitalization, need for crisis intervention, clinical decision that oral antipsychotic medication cannot be discontinued in less than eight weeks, a clinical decision to discontinue the medication due to inadequate benefit, or the ongoing or repeated need for adjunctive antipsychotic medication.</description>
        <time_frame>24 months</time_frame>
        <population>All randomized participants who received an injection and attended one follow-up appointment</population>
        <group_list>
          <group group_id="O1">
            <title>Paliperidone Palmitate</title>
            <description>Intramuscular injections of paliperidone palmitate 39-234 mg every month</description>
          </group>
          <group group_id="O2">
            <title>Haloperidol Decanoate</title>
            <description>Intramuscular injections of haloperidol decanoate 25-200 mg every month</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy Failure</title>
          <description>Efficacy failure as indicated by psychiatric hospitalization, need for crisis intervention, clinical decision that oral antipsychotic medication cannot be discontinued in less than eight weeks, a clinical decision to discontinue the medication due to inadequate benefit, or the ongoing or repeated need for adjunctive antipsychotic medication.</description>
          <population>All randomized participants who received an injection and attended one follow-up appointment</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="145"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Psychiatric Symptoms</title>
        <description>The Positive and Negative Syndrome Scale measures the core symptoms associated with schizophrenia. The measure includes 30 items rated from 1=absent to 7=extremely severe. Full range of scores is 30-210 with higher scores representing more severe illness. Reductions in symptoms over time represent improvement.</description>
        <time_frame>Baseline to 6 months</time_frame>
        <population>Participants with PANSS scores at 6 months</population>
        <group_list>
          <group group_id="O1">
            <title>Paliperidone Palmitate</title>
            <description>Intramuscular injections of paliperidone palmitate 39-234 mg every month</description>
          </group>
          <group group_id="O2">
            <title>Haloperidol Decanoate</title>
            <description>Intramuscular injections of haloperidol decanoate 25-200 mg every month</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Psychiatric Symptoms</title>
          <description>The Positive and Negative Syndrome Scale measures the core symptoms associated with schizophrenia. The measure includes 30 items rated from 1=absent to 7=extremely severe. Full range of scores is 30-210 with higher scores representing more severe illness. Reductions in symptoms over time represent improvement.</description>
          <population>Participants with PANSS scores at 6 months</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="88"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.87" lower_limit="-8.79" upper_limit="-4.94"/>
                    <measurement group_id="O2" value="-6.40" lower_limit="-8.32" upper_limit="-4.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Paliperidone Palmitate</title>
          <description>Intramuscular injections of paliperidone palmitate 39-234 mg every month</description>
        </group>
        <group group_id="E2">
          <title>Haloperidol Decanoate</title>
          <description>Intramuscular injections of haloperidol decanoate 25-200 mg every month</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Suicidal Act</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Homicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Homocidal Act</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Violent ideation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Violent act</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Psychiatric hospitalization</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="100" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="88" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Orthostatic faintness</sub_title>
                <description>Events rated moderate or severe</description>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry mouth</sub_title>
                <description>Events rated moderate or severe</description>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="34" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <description>Events rated moderate or severe</description>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Increased appetite</sub_title>
                <description>Events rated moderate or severe</description>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Sialorrhea</sub_title>
                <description>Events rated moderate or severe</description>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <description>Events rated moderate or severe</description>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Sleepiness</sub_title>
                <description>Events rated moderate or severe</description>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Hypersomnia</sub_title>
                <description>Events rated moderate or severe</description>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Incontinence/nocturia</sub_title>
                <description>Events rated moderate or severe</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="147"/>
              </event>
              <event>
                <sub_title>Urinary hesitancy</sub_title>
                <description>Events rated moderate or severe</description>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menstrual irregularities</sub_title>
                <description>Events rated moderate or severe</description>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="147"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="147"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>T. Scott Stroup</name_or_title>
      <organization>Columbia University</organization>
      <phone>646-774-8435</phone>
      <email>stroups@nyspi.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

